Sacituzumab Govitecan
Brand Names: Trodelvy
Methodology & AI Transparency ⓘ
Sacituzumab Govitecan Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage trodelvy: is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated: Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line As a single agent for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor-based therapy.
- 2 Real-world patient consensus: Tracked across 21 patient dosage logs with a 92% satisfaction benchmark (RxCUI 2360534).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $117.04 cash mean against $286.75 retail pharmacy pricing.
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Sacituzumab Govitecan): nausea (10.8%), diarrhea (8.1%), fatigue (8.5%).
Ask our AI Specialists anything about Sacituzumab Govitecan
Sacituzumab Govitecan Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage trodelvy: is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated: Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line As a single agent for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor-based therapy.
12.1 Mechanism of Action Sacituzumab govitecan-hziy is a Trop-2-directed antibody-drug conjugate. Sacituzumab is a humanized antibody that recognizes Trop-2. The small molecule, SN-38, is a topoisomerase I inhibitor, which is covalently attached to the antibody by a linker. Pharmacology data suggest that sacituzumab govitecan-hziy binds to Trop-2-expressing cancer cells and is internalized with the subsequent release of SN-38 via hydrolysis of the linker. SN-38 interacts with topoisomerase I and prevents re-ligation of topoisomerase I-induced single strand breaks. The resulting DNA damage leads to apoptosis and cell death.
Clinical clearance of Sacituzumab Govitecan (FDA Prescription Therapeutic Agent) relies on hepatic oxidation via ugt1a1 followed by renal and biliary excretion of sacituzumab govitecan metabolites with a Approximately 3–8 hours terminal plasma half-life for Sacituzumab Govitecan half-life; patients absorbing at Estimated 70%–82% oral systemic absorption for Sacituzumab Govitecan bioavailability typically observe target onset around peak plasma concentration (tmax) reached 1–2 hours post-dose for sacituzumab govitecan.
FDA clinical labeling for Sacituzumab Govitecan restricts administration in 4 contraindications trodelvy is contraindicated in patients who have experienced a severe hypersensitivity reaction to trodelvy .; severe hypersensitivity reaction to trodelvy. across 180 mg/1 Powder, for Solution, Longitudinal Sacituzumab Govitecan dosing interval tailored to tolerability, with self-reported patient tracking dominated by nausea (10.8% of reports), fatigue (8.5% of reports), diarrhea (8.1% of reports).
Review concurrent UGT1A1 substrates and inhibitors when titrating Sacituzumab Govitecan maintenance doses.
Assess baseline hepatic panels and interacting prescriptions when starting Sacituzumab Govitecan (fda prescription therapeutic agent).
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- 4 CONTRAINDICATIONS TRODELVY is contraindicated in patients who have experienced a severe hypersensitivity reaction to TRODELVY .
- Severe hypersensitivity reaction to TRODELVY.
Logged Side-Effect Incidence (21 Reports)
Sacituzumab Govitecan Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Sacituzumab Govitecan)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Sacituzumab Govitecan Population how the body absorbs the medicine: Updated: What a 260-Participant Study Found The analyses confirmed mild-to-moderate kidney impairment, mild liver impairment, age, tumor type (based on limited data in non-breast cancer tumor types), baseline albumin level, UGT1A1 genotype, or Trop-2 expression did not... Clinical and translational science • 2025-07-15 • Phase III Randomized Trial | N = 260 | 87/100 | PMID 40657894 ↗ |
| Can This Approach Help? Inside the Latest Research on Summary of quality of life in the ASCENT phase 3 clinical trial for people with However, they experienced worsening of diarrhea and/or nausea/vomiting. Future oncology (London, England) • 2024-01-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39324726 ↗ |
Sacituzumab Govitecan Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.6800/unit (~$80.40/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $286.75 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 21 Anonymous DotMD Community Micro-Logs | $117.04 / mo | View logs ↓ |
Sacituzumab Govitecan Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Sacituzumab Govitecan RxNorm Concept ID | 2360534 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.6800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $286.75 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $117.04 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 92.00% Worth It (21 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Sacituzumab Govitecan Patient Community, Cohort Filters & Dosage Logs
Deterministic Sacituzumab Govitecan reference combining NIH RxNorm (2360534), Medicaid NADAC ($2.6800/unit), and anonymous cohort outcomes (92% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Sacituzumab Govitecan community threads and patient logs by age, biological sex, dosage, and treatment duration.